Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination

Journal of Immunology

Volumn 183, Issue 7, 2009, Pages 4800-4808

  Tsuji, Takemasa ^a   Altorki, Nasser K ^b   Ritter, Gerd ^a   Old, Lloyd J ^a   Gnjatic, Sacha ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; MELANOMA ANTIGEN 3; OLIGOCLONAL BAND; CANCER VACCINE; EPITOPE; IMMUNOLOGICAL ADJUVANT; MAGEA3 PROTEIN, HUMAN; SUBUNIT VACCINE; TUMOR ANTIGEN; TUMOR PROTEIN;

ADJUVANT THERAPY; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CANCER IMMUNIZATION; CANCER PATIENT; CD4+ T LYMPHOCYTE; CELL SELECTION; CELL SPECIFICITY; CONTROLLED STUDY; HLA SYSTEM; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN VACCINATION; T LYMPHOCYTE ACTIVATION; CD4 LYMPHOCYTE COUNT; CELL LINE; COCULTURE; COMPARATIVE STUDY; CYTOLOGY; IMMUNIZATION; IMMUNOLOGY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; LYMPHOCYTE ACTIVATION; PATHOLOGY; TIME; TUMOR CELL CULTURE;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TRANSFORMED; COCULTURE TECHNIQUES; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNIZATION, SECONDARY; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; NEOPLASM PROTEINS; TIME FACTORS; TUMOR CELLS, CULTURED; VACCINES, SUBUNIT;

EID: 70449732761     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0900903     Document Type: Article

References (34)

1. Jager, E., Y. Nagata, S. Gnjatic, H. Wada, E. Stockert, J. Karbach, P. R. Dunbar, S. Y. Lee, A. Jungbluth, D. Jager, et al. 2000. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc. Natl. Acad. Sci. USA 97: 4760-4765.
2. + T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc. Natl. Acad. Sci. USA 100: 8862-8867.
3. Kubuschok, B., F. Neumann, R. Breit, M. Sester, C. Schormann, C. Wagner, U. Sester, F. Hartmann, M. Wagner, K. Remberger, M. Schilling, and M. Pfreundschuh. 2006. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer. Clin. Cancer Res. 12: 1365-1372.
4. + T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. Cancer Res. 63: 5601-5606.
5. + T cell responses in humans. Proc. Natl. Acad. Sci. USA 101: 10697-10702.
6. Jager, E., J. Karbach, S. Gnjatic, A. Neumann, A. Bender, D. Valmori, M. Ayyoub, E. Ritter, G. Ritter, D. Jager, et al. 2006. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc. Natl. Acad. Sci. USA 103: 14453-14458.
7. Odunsi, K., F. Qian, J. Matsuzaki, P. Mhawech-Fauceglia, C. Andrews, E. W. Hoffman, L. Pan, G. Ritter, J. Villella, B. Thomas, et al. 2007. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc. Natl. Acad. Sci. USA 104: 12837-12842.
8. + T cells following peptide vaccination. J. Immunol. 176: 6340-6346.
9. + helper T cell responses in cancer patients. Blood 106: 1008-1011.
10. + T cells. Cancer Immunol. Immunother. 57: 833-847.
11. Danke, N. A., D. M. Koelle, C. Yee, S. Beheray, and W. W. Kwok. 2004. Autoreactive T cells in healthy individuals. J. Immunol. 172: 5967-5972.
12. Hasegawa, K., Y. Noguchi, F. Koizumi, A. Uenaka, M. Tanaka, M. Shimono, H. Nakamura, H. Shiku, S. Gnjatic, R. Murphy, et al. 2006. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: identification of a new HLA-DR15-binding CD4 T-cell epitope. Clin. Cancer Res. 12: 1921-1927.
13. Van den Eynde, B. J., and P. van der Bruggen. 1997. T cell defined tumor antigens. Curr. Opin. Immunol. 9: 684-693.
14. + T cells. Cancer Res. 68: 1555-1562.
15. + cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J. Exp. Med. 189: 871-876.
16. + T cell responses to MAGE-3 protein in lung cancer patients. J. Immunol. 172: 3289-3296.
17. Atanackovic, D., N. K. Altorki, Y. Cao, E. Ritter, C. A. Ferrara, G. Ritter, E. W. Hoffman, C. Bokemeyer, L. J. Old, and S. Gnjatic. 2008. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc. Natl. Acad. Sci. USA 105: 1650-1655.
18. Vantomme, V., C. Dantinne, N. Amrani, P. Permanne, D. Gheysen, C. Bruck, G. Stoter, C. M. Britten, U. Keilholz, C. H. Lamers, et al. 2004. Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J. Immunother. 27: 124-135.
19. + T cell responses against viral and tumor antigens using T cells as novel target APC. J. Immunol. Methods 278: 57-66.
20. + T cells with diverse cytokine profiles. Nat. Med. 11: 1113-1117.
21. Cousins, D. J., T. H. Lee, and D. Z. Staynov. 2002. Cytokine coexpression during human Th1/Th2 cell differentiation: direct evidence for coordinated expression of Th2 cytokines. J. Immunol. 169: 2498-2506.
22. Martin, M., S. M. Michalek, and J. Katz. 2003. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect. Immun. 71: 2498-2507.
23. Sharma, P., D. F. Bajorin, A. A. Jungbluth, H. Herr, L. J. Old, and S. Gnjatic. 2008. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J. Immunother. 31: 849-857.
24. Valmori, D., N. E. Souleimanian, V. Tosello, N. Bhardwaj, S. Adams, D. O'Neill, A. Pavlick, J. B. Escalon, C. M. Cruz, A. Angiulli, et al. 2007. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc. Natl. Acad. Sci. USA 104: 8947-8952.
25. Uenaka, A., H. Wada, M. Isobe, T. Saika, K. Tsuji, E. Sato, S. Sato, Y. Noguchi, R. Kawabata, T. Yasuda, et al. 2007. T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun. 7: 9.
26. Wang, X. F., W. M. Cohen, F. A. Castelli, C. Almunia, B. Lethe, S. Pouvelle-Moratille, G. Munier, D. Charron, A. Menez, H. M. Zarour, et al. 2007. Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family. Cancer Immunol. Immunother. 56: 807-818.
27. + T cells in cancer-free individuals. Clin. Immunol. 117: 161-167.
28. + T cells specific for the tumor antigen SSX-1 in cancer-free individuals. Cancer Immunol. Immunother. 56: 1183-1192.
29. + T cells against NY-ESO-1. N. Engl. J. Med. 358: 2698-2703.
30. Maxwell, J. R., R. J. Rossi, S. J. McSorley, and A. T. Vella. 2004. T cell clonal conditioning: a phase occurring early after antigen presentation but before clonal expansion is impacted by Toll-like receptor stimulation. J. Immunol. 172: 248-259.
31. Scholer, A., S. Hugues, A. Boissonnas, L. Fetler, and S. Amigorena. 2008. Intercellular adhesion molecule-1-dependent stable interactions between T cells and dendritic cells determine CD8+ T cell memory. Immunity 28: 258-270. (Pubitemid 351222655)
32. Bachmann, M. F., D. E. Speiser, T. W. Mak, and P. S. Ohashi. 1999. Absence of co-stimulation and not the intensity of TCR signaling is critical for the induction of T cell unresponsiveness in vivo. Eur. J. Immunol. 29: 2156-2166.
33. + T cells by bacterial vector. Blood 111: 1404-1412.
34. Van den Eynde, B. J., and T. Boon. 1997. Tumor antigens recognized by T lymphocytes. Int. J. Clin. Lab. Res. 27: 81-86.